quinoxalines has been researched along with Facial Dermatoses in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fowler, J; Jackson, M; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M | 1 |
| Benkali, K; Bouer, R; Fernando, A; Graeber, M; Leoni, M; Rony, F; Wagner, N | 1 |
| Fowler, J; Jarratt, M; Leoni, M; Liu, Y; Meadows, K; Moore, A; Pollack, A; Steinhoff, M | 1 |
| Ratan, J; Sodhi, PK; Verma, L | 1 |
| Brodsky, MC; Scruggs, JT; Whiteside-Michel, J | 1 |
| Frías, J; Hernández-Carrasco, S; Martínez-Escribano, J; Rodríguez, M; Sánchez-Pedreño, P | 1 |
3 trial(s) available for quinoxalines and Facial Dermatoses
| Article | Year |
|---|---|
Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Facial Dermatoses; Female; Follow-Up Studies; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2013 |
Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Area Under Curve; Biological Availability; Brimonidine Tartrate; Drug Administration Schedule; Facial Dermatoses; Female; Gels; Humans; Male; Ophthalmic Solutions; Quinoxalines; Rosacea | 2014 |
Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Brimonidine Tartrate; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome; Young Adult | 2012 |
3 other study(ies) available for quinoxalines and Facial Dermatoses
| Article | Year |
|---|---|
Dermatological side effects of brimonidine: a report of three cases.
Topics: Administration, Topical; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Dermatitis, Allergic Contact; Diagnosis, Differential; Facial Dermatoses; Female; Glaucoma, Open-Angle; Humans; Lichen Planus; Male; Nail Diseases; Ocular Hypertension; Ophthalmic Solutions; Patch Tests; Quinoxalines | 2003 |
The teardrop sign: a rare dermatological reaction to brimonidine.
Topics: Adrenergic alpha-Agonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Drug Eruptions; Facial Dermatoses; Humans; Male; Quinoxalines | 2000 |
Occupational photoallergic contact dermatitis to olaquindox.
Topics: Animal Husbandry; Animals; Dermatitis, Occupational; Dermatitis, Photoallergic; Diagnosis, Differential; Facial Dermatoses; Humans; Male; Middle Aged; Patch Tests; Quinoxalines; Swine | 2001 |